Delivery Order SPE2DB20D7059-SPE2DB25FQBA2

Award Date 2/28/25
Potential Completion Date 3/3/25
Potential Value $1.7K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of Methotrexate 2.5 mg tablets in quantities of 100 to the Defense Logistics Agency (DLA) Troop Support Medical. The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. The contract has a ceiling value of $9,155.75 and is a delivery order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which has a potential value of up to $999,999,999.00 and...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,500.64, is for the delivery of Methotrexate 2.5 mg tablets (100 count) to support military healthcare programs. The contract is a Delivery Order with a Firm Fixed Price pricing type and has a completion date of May 22, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Methotrexate 2.5 mg tablets. The award, valued at $6,197.51, is a firm fixed-price delivery order contract with a completion date of May 16, 2024. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award, valued at $1,563.22, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp. The contract is for the delivery of 4,565,634,382 units of Methotrexate 2.5 mg tablets. The contract has a completion date of August 30, 2024 and is a Firm Fixed Price Delivery Order. This contract is not designated as a set-aside. AmerisourceBergen, a major pharmaceutical distributor, has been awarded multiple Indefinite Delivery Contracts (IDCs) by the DLA and...
The federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the delivery of 4,565,843,623 units of Methotrexate 2.5 mg tablets. The $3,853.16 firm fixed-price award is a delivery order issued by the Defense Logistics Agency (DLA) Troop Support Medical, a defense agency. The contract has an ultimate completion date of September 18, 2024 and does not use a set-aside designation. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the...
This federal contract award, valued at $6,032.75, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the delivery of Methotrexate 2.5 mg tablets. The contract is a Firm Fixed Price Delivery Order that runs through November 2024. AmerisourceBergen, a major pharmaceutical distributor, holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical worth up to $999,999,999 through November 2026. This IDC serves as a primary vehicle for...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,336.53, is for the delivery of 4,566,294,418 units of Methotrexate 2.5 mg tablets, a medication used to treat various medical conditions. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at...
This federal contract award is a delivery order (SPE2DB20D1100|SPE2DB25FY70K) issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $3,174.36 firm-fixed-price contract is for the delivery of Methotrexate 2.5 mg tablets, a medication used to treat various conditions. The contract has an ultimate completion date of October 25, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Methotrexate 2.5 mg tablets. The $4,588.56 firm fixed-price delivery order has a completion date of December 29, 2023. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC serves as the primary vehicle...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,951.56 Firm Fixed Price Delivery Order covers the supply of 4,565,087,756 units of Methotrexate 2.5 mg Tablets in 100-count bottles, with a completion date of July 9, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract with the DLA Troop Support Medical, which serves as the primary vehicle...
  • SPE2DB20D7059
    Indefinite Delivery Contract
  • SPE2DB20D7059-SPE2DB25FQBA2
    Delivery Order

This federal contract award is for the delivery of Methotrexate 2.5 mg tablets to the Defense Logistics Agency (DLA), a defense agency. The contract, valued at $1,653.72, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract has no set-aside designation, indicating open competition. The award covers critical medical commodities including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains to meet the healthcare needs of military personnel, veterans, and other federal beneficiaries.

Generated 5/30/25, 10:09 AM